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ABSTRACT 
 
Background: 
Ulcerative Colitis (UC) is a chronic inflammatory bowel disease; the etiology is 
mainly unknown. Around 30% of the patients are treated by surgery. The aims 
of this thesis were to evaluate outcome after specific surgical procedures and to 
investigate possible pathophysiological aspects. 
Methods:  
Functional outcome after ileal pouch-anal anastomosis (IPAA) and ileo-rectal 
anastomosis (IRA) was recorded by Öresland score; different pouch designs (K  
or J ) were compared. Frequency of neoplasia in IPAA:s was evaluated in 
patients with previous neoplasias. Patients with UC and primary sclerosing 
cholangitis (PSC) were compared to patients with UC-only regarding outcome 
of IPAA or IRA. Galectin expression was investigated in full wall specimens 
from patients with UC.  
Results:  
IPAA:s with K -design and stapled anastomosis were associated with better 
Öresland score than IPAA:s with J-design. The obtained frequency of dysplasia 
in IPAA:s was 1.8% (95%-CI: 0-5.3%) in patients with previous neoplasia. 
Patients with UC-PSC operated on with IPAA have similar outcome as patients 
with UC-only, except for higher incidence of pouchitis. Patients with IRA in the 
same setting, have worse functional outcome and an increased rate of failure. 
There was no correlation between galectin expression and inflammatory grade. 
Conclusions:  
K -design was associated with best functional outcome; however, the study was 
non-randomized. The frequency of dysplasia after IPAA is low, even in a 
selected risk group. IPAA seems superior to IRA in patients with UC-PSC. The 
role of galectins in the pathogenesis of UC remains to be elucidated. 
Keywords: Ulcerative Colitis, Long-term function, IPAA, IRA, Neoplasia, 
Surveillance, Primary Sclerosing Cholangitis, Galectins, Immunohistochemistry 
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INTRODUCTION 
Background 
“Morbid appearances in the intestine of Miss Bankes” is considered the first 
description of Ulcerative Colitis (UC) by Samuel Wilks (Fig. I), Guy Hospital, 
London, UK in 18591. He did an autopsy of a 42 year-old woman who died 
after several months of diarrhoea and fever, demonstrating transmural ulcerative 
inflammation of the colon, differentiating it from bacterial dysentery.  
 
UC is a chronic, relapsing inflammatory condition of the large intestine that 
affects individuals, often young, throughout life, although individuals of any age 
can be affected2,3. UC has an incidence in the Western world of 10-15/100.000 
inhabitants and around 2.1 millions individuals 
are estimated to live with UC in Europe4. The 
onset is often between 20 and 35 years of age. 
The disease is slightly more common among 
females (1.2:1)5. The inflammation often begins in 
the rectum and spreads proximally in a 
continuous fashion2. Depending on the anatomic 
extent, patients can be classified as suffering from 
proctitis, left-sided colitis or pancolitits, the latter 
affecting almost the entire colon (Fig. II)3. 
Symptoms of UC are typically bloody diarrhoea, 
abdominal cramping and passage of pus or 
mucus; symptoms are often less severe in left-
sided colitis and proctitis3.  
The aetiology and pathogenesis of UC are 
essentially unknown, but involves complex 
interactions between intestinal micro flora, host genetic- and immune factors, as 
well as environmental stimuli6-13. 
 
Up to 25-40% of patients with UC will develop extraintestinal manifestations 
that can affect various other organs such as joints, skin, bile ducts, eyes, lungs, 
and pancreas14. Most common are peripheral arthritis, erythema nodosum and 
pyoderma gangrenosum14. Anemia is also common, usually due to the 
combination of severe chronic inflammation and/or bleeding of the bowel. 
Extraintestinal manifestations usually respond to treatment of the inflamed 
bowel. There is, however, a need for multidisciplinary disposing of UC patients  
Figure I. Dr. Samuel Wilks. 
Courtesy US National Library 
of Medicine. 
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with extraintestinal manifestations involving surgeons, gastroenterologists, 
rheumatologists and others14.  
The total cost for healthcare (and sick leave) for UC is around 2.7-3.2 billions 
Euro/year in Europe4. The unemployment among the patients is around 10% 
and around 25% work part-time. Around 20% of the patients are early retired 
from their working life4. 
 
 
Pathophysiological Aspects 
 
The etiology of UC involves an interaction between genetic- and non-genetic 
factors. The main theory of the pathophysiology of UC is an abnormal 
inflammatory response to bacterial contents in the intestinal lumen, in 
genetically predisponed patients6-13. 
Studies have identified 99 overlapping genetic risk loci for UC (28 shared with 
Crohn´s disease). However, the concordance rate in monozygotic twins is 
around 10-15%15,16. This observation favours the idea that non-genetic factors 
may play an important role in UC17. 
The intestinal mucosal cells act as a barrier, but they also care for delicate signal-
functions between the host and the complex luminal milieu, dominated by 
bacteria. Maintaining a perfect balance between the two roles is central. Tight 
junctions between the mucosal cells18,19, as well as the mucus layer, can be 
disrupted in UC20,21. These alterations can lead to translocation of bacteria from 
the lumen into underlying tissues and further to the circulation, creating a 
powerful inflammatory response2,13. The response leads to continuous epithelial 
damage, with erosions and ulcerations and a further breakdown of local defense 
mechanisms22,23. See Figure III. 
 
Figure II. Different 
anatomical extent of UC; 
proctitis, proctosigmoiditis, 
and left-sided colitis. 
Pancolitis is inflammation 
beyond the middle of the 
transverse colon or of the 
entire colon. Courtesy US 
National Library of Medicine. 
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   A)                           B)                      C) 
 
Figure III A-C. Colonic mucosa, from left to right; A) normal mucosa, B) UC; mild (cryptitis) 
and moderate (crypt abscess) inflammation, and C) severe (ulceration) inflammation  
 
Typical for UC is infiltration into the lamina propria of innate immune cells 
(dendritic cells, macrophages and neutrophils), as well as adaptive immune cells 
(B- and T-cells)24. The increased number of active inflammatory cells result in 
an increased level of cytokines, interleukines and interferons25. 
 
 
Treatment 
 
The first line of treatment is pharmaco log i ca l  therapy 26,27. Corticosteroids and 
5-ASA were the first pharmacological agents used26,28. Nowadays, more effective 
alternatives such as immunomodulators and biological agents (anti-TNF) are 
available. Although the pharmacological (non-surgical) treatment has improved 
over the years, around 30% of patients with UC will be operated upon during 
their lifetime3,29. There are two principal reasons for surgical treatment: 1) 
medically refractory disease in a chronic (50% of surgery) or acute (40%) setting, 
and 2) development of dysplasia or carcinoma (10%)30. Patients with extensive 
colitits are at higher risk of surgery (30%), compared to patients with left-sided 
colitis (5%), or proctitis alone (2%)31. Emergency surgery is indicated when the 
patient presents with a life-threatening complication, such as perforation, 
refractory bleeding, or toxic megacolon32,33. Since most patients have a long life 
expectancy, perfect surgical techniques are of outmost importance for assuring 
best possible outcome34. 
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Surgery 
 
When non-surgical treatment has failed and surgery is considered indicated, it is 
vital to address the patient with information of the surgical options and their 
expected outcome. Several aspects should be covered: postoperative 
complications, functional outcome, health-related quality of life (HQoL), 
reproduction, and the risk for proctitis/pouchitis34,35. Furthermore, the patients 
need to be informed about future medication, follow-up regims (considering the 
risk for carcinoma) and failure rates of surgical reconstructions35-39. 
Patients with UC, preferably young and active, usually have a strong desire for 
defecation through the normal route. Thus, the principal aim of the techniques 
that have evolved throughout the years, has been to offer most patients an 
option that not includes a conventional stoma.  
 
The initial procedure in most patients is abdominal colectomy (removal of the 
entire colon to the rectum) and deviation with an ileostomy30,32. For the majority 
of patients, the final goal is to restitute bowel continuity and the main surgical 
options are ileo-rectal anastomosis (IRA)40,41 or protectomy with ileal pouch-
anal anastomosis 
(IPAA)42,43. The 
procedures can be done 
in one-, two- or three- 
steps.  
Proctocolectomy with 
ileostomy30, or 
proctocolectomy with 
continent ileostomy (CI; 
Kock pouch)44 are other 
options. See Figure IV.  
Segemental colon 
resection has been 
reported45 and can be 
associated with better 
functional outcome. 
However, the technique 
is not widespread45. 
Of outmost importance 
is the communication 
between the surgeon 
and the well-informed 
patient32. To date, there 
Figure IV. Surgical options for treatment of ulcerative colitis; 
A, proctocolectomy; B, Brooke ileostomy; C, Koch pouch 
(continent ileostomy); D, Ileal Pouch-anal Anastomosis (IPAA). 
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are no prospective, randomized trials comparing the main surgical options in 
UC. 
Ileo-Rectal Anastomosis (IRA) 
Lilienthal was the first surgeon who performed an IRA (or more common an 
ileo-sigmoidal anastomosis) for patients with UC, in the beginning of the 
1900s46. See Figure V. This was considered a great innovation compared to 
previous surgical options, wich included appendicostomy (with irrigation), 
caecostomy or loop ileostomy. However, due to fear of the long-term risk of 
neoplasia and for the risk of poor functional outcome, IRA was never 
widespread. In the 50´s, Aylett47 started to use the technique more extensively 
and he became a strong protagonist for IRA. Aylett reported an operative 
mortality of 5% and 90% of the patients were restored to health48. Others 
(among them Goligher), were very sceptic to the procedure49. In the late 70´s, 
Baker et al reported a carcinoma-
risk of 6% after 20 years, increasing 
to 18% after 35 years50. In the early 
90´s, Leijonmark reported no 
carcinoma after a mean follow up of 
13 years51. However, failure rate was 
more than 50%, the majority due to 
recurrent inflammation of the 
rectum51. The risk for ongoing 
inflammation in the rectum/distal 
colon, for symptomatic relapse and 
for development of dysplasia and 
carcinoma, limited the use of IRA. 
 
The advantage of IRA compared to IPAA (see below) is less surgical trauma 
without pelvic dissection and thus a lesser risk for complications52 such as 
incontinence, impotence, reduced fecundability and dyspareunia41. The 
challenge is the patient selection36,46. Most likely, compliance of the rectum is the 
most important factor41,51. When the rectum shows signs of severe inflammation 
and is non-compliant, or on the other hand shows a normal mucosa with good 
compliance, the choice of avoiding or performing an IRA is usually easy36,46. 
However, when the patient presents with moderate inflammation and some 
grade of decreased compliance, the management is more difficult41. 
Complications rates after IRA varies between 12 and 25%40,41,52. Failure rate 
nowdays is about 15-19% after five years and up to 30% after ten years52-54. If 
the IRA fails, one option can be IPAA. 
Figure V. Ileorectal anastomosis (IRA). 
Courtesy US National Library of Medicine. 
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No study has compared IRA and IPAA in patients with UC with fecundability 
as primary endpoint. However, in a study of female patients with Familial 
Adenomatous Polyposis, the fecundity dropped to 54% after IPAA, while 
patients with IRA had the same fecundity as the background population55. In 
present-day Scandinavia, IRA is perhaps considered the main option for 
reconstruction of intestinal continuity32,40,51,52,54, especially in women with the 
prospect of future pregnancy. Although IPAA is mostly advocated throughout 
the rest of the international surgical society, IRA is slowly becoming an 
alternative option, e.g. in Spain, but also in some parts of the UK.  
Ileal Pouch-Anal Anastomosis (IPAA) 
Since the early 80s, IPAA has been the prefered procedure for the majority of 
surgeons and the 
operation has evolved 
from a complicated, 
high-morbidity 
procedure to a fully 
evaluated and safe one56. 
The possibility of 
eliminating all diseased 
bowel and avoid a 
permanent ileostomy 
has apparent advantages 
compared to other 
options. Ravitch and 
Sabiston have been 
given the credit of 
pioneering this 
operation with 
experiments in dogs in 
194757. Subsequent surgery in patients was however associated with severe 
morbidity and the authors felt obliged to advise against the procedure. Several 
surgeons tried to develop similar procedures during the 50s and 60s (Goligher, 
Drobni, Martin, Valiente). However, they still experienced major 
complications58-60. Only half of the patients achieved continence and around 
40% eventually required a permanent ileostomy59.  
Parks and Nicholls presented the IPAA in 197842. Functional outcome was 
reported as good, except for problems with pouch emptying; more than 50 % of 
the patients had to use a catheter for evacuation. This was due to the long 
pouch outlet in the initial design, the so-called S -pouch61.  
Figure VI. Construction of IPAA (in this case a J-pouch). 
The ileo-anal anastomosis is hand-sewn in this case. 
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A)                       B)                C) 
 
Figure VII. Construction of the IPAA (the pouch). A) First step. B) J-pouch. C) K-pouch. 
 
Utsunomiya developed the J-pouch in the 1980s (Fig. VI and VIIB)43. The 
design was initially spread in Japan and in the US; the technique is the most 
commonly used today. The W -pouch (promoted by Nicholls) is associated with 
a larger pouch volume; however, the design includes additional intestinal length 
in the pouch61. 
Yet another design is to fold the pouch as a Kock pouch, omitting the nipple 
segment (see below; K -poch). The advantage of a K -pouch is that it develops a 
spherical design, resulting in a proportionally larger volume for the length of 
ileum used62. Furthermore, the K -pouch reduces the dead space in the small 
pelvis and there is some evidence that the K -pouch (as well as the W -pouch56) 
could have a slightly superior function. Usually, the IPAA is performed with a 
diverting temporary loop ileostomy as part of the procedure, but in selected 
cases, it may be omitted63,64. 
Hand-sewn versus Stapled Anastomosis  
When performing an IPAA, two different techniques are used for the 
anastomosis between the pouch and the anus: hand-sewn anastomosis with 
mucosectomy, versus stapled anastomosis (Fig. VIII)65,66. Most studies show a 
slightly better functional outcome after stapled anastomosis67,68, especially 
regarding continence68,69. The stapled technique is technically simpler, but 
patients may be at risk for developing cuffitis, ie symptomatic inflammation of 
the anal transitional zone (ATZ)84, 86. (The ATZ occupies the area from 1 to 1.5 
cm above the lower border of the internal sphincter, and have squamous 
epithelium below and columnar epithelium above. Mainly, the ATZ is 
composed of transitional epithelium70. This area will be referred to as the ATZ 
throughout this thesis.) 
Cuffitis, or strip proctitis, can be symptomatic in 25% of patients71.  
Theoretically, mucosectomy protects the patient from development of dysplasia, 
since all rectal mucosa is removed. However, several studys have shown that 
Mattias Block 
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this is not the case; mucosectomy does not completely protect patients from 
developing dysplasia in the ATZ29,72,73 (See below “Histopathology and 
Neoplasia in IPAA”). 
 
 
 A)                      B) 
 
Figure VIII. Construction of IPAA (the ileo-anal anastomosis). A) Stapled anastomosis with a 
circular stapler-device. B) Hand-sewn anastomosis with mucosectomy. 
 
Proctocolectomy and Ileostomy  
 
Although IRA or IPAA are the main surgical options after abdominal 
colectomy, an alternative is proctocolectomy and conventional ileostomy. 
Historically, ileostomy with eversion of the mucosa was first described by 
Brooke in 195274, considerably improving quality of life for ostomists. Before 
that, ileostomies were associated with pronounced problems, mainly due to skin 
stenosis and poorly functioning stomal appliances. Compared to IPAA, the 
procedure is associated with lower risk for short- and long-term complications. 
Informed patients who choose a permanent ileostomy have a HQoL similar to 
patients with IPAA75. The procedure remains a valid option, preferably in 
patients with co-morbidity, not fit for IPAA. Furthermore, for some patients 
who prefer a stoma, or do not want to take the risks associated with IPAA (or 
IRA)76.  
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Continent Ileostomy (Kock 
pouch) 
 
The continent ileostomy (CI; Kock pouch) 
was developed by the Swedish surgeon Nils 
Kock and was first presented 196944. See 
Figure IX. The CI is a well functioning 
alternative to a conventionel ileostomy. The 
major problem is the long-term need for 
surgical revisions (around 25% major 
revisions and 15% local procedures at 15 
years77). The CI could be an option when 
there are technical difficulties in performing 
an IPAA (i.e. lack of bowel length) or 
perianal disease, including fistulas and incontinence. An IPAA can sometimes be 
converted to a continent ileostomy; in a study from Sahlgrenska University 
Hospital on that procedure, 10/13 patients reported satisfactory function after 
median 6 years78.  
Complications after IPAA 
An important aspect of IPAA is that the procedure is associated with some well-
known complications; these can be separated into early or late. Early 
complications are common, with a range of 30-50% in large series37,38,56. In 
general terms, early complications do not differ from those seen after other 
major abdominal surgery. However, late complications (pouchitis, fistula, 
stricture of the ileo-anal anastomosis) are specific problems observed after 
IPAA. Both early and late complications can ultimately lead to pouch failure.  
Early Complications: 
Early complications after surgery are bleeding, anastomotic leak (4-7%)56,79,80, 
pelvic abscess35, intestinal obstruction (10-30%)35,81,82 and stenosis of the ileo-
anal anastomosis (8-22%)35. The complications should be treated according to 
general surgical principels. It is important to rule out a potential fistula before 
ileostomy closure. An abscess adjacent to the IPAA could affect long-term 
function and thus, rapid drainage is mandatory37.  
Late Complications: 
Late complications can be defined as complications evident after closure of the 
diverting loop ileostomy, or after more than 90 days after IPAA35. These include 
Figure IX. The continent ileostomy 
(CI; Kock pouch). By permission of 
stomavice.co.uk. 
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septic complications (pelvic sepsis or fistulas), stricture of the ileo-anal 
anastomosis, intestinal obstruction, pouchitis and pouch failure34. Neoplasia 
cannot be considered a complication to surgery, but rather a complication to the 
disease itself, (see below, Histopathology and Neoplasia in IPAA). 
The incidence of pelvic sepsis varies from 5-40%35,38,83-87, depending on 
definition and length of follow-up. Patient selection could affect the rate of 
pelvic sepsis; risk factors are ongoing treatment with steroids83, Crohn´s 
disease88 and perianal disease88. Several studies have shown that a septic 
complication (early or late) is a common reason for pouch failure35,84,89. Since 
septic complications can emerge surprisingly late after IPAA (years),83,84 the 
patient condition, symptoms and type of complication affect timing and method 
of choice for treatment84. 
A feared late complication is fistulas, pouch-vaginal being the most 
common90,91. The majority of fistulas develop 6-24 months after surgery88 and 
are mainly considered as a late complication. Around 50% of patients with 
pouch-vaginal fistulas eventually achieve recovery; however 25% still have 
fistulous discharge, but remain with the IPAA, whereas 25% need diversion or 
excision of the IPAA (failure)92. Other fistulas are pouch-perineal, pouch-
cutaneous and pouch-presacral. Optional treatment varies from local repair to 
major surgical procedures (re-do). The reported succes rates after major surgery 
varies, but is around 50%, depending on type of fistula and extent of 
procedure90,91,93. 
Another late complication is development of an anastomotic sinus – a chronical 
cavity in the pelvis, almost mandatory behind the ileal pouch. Sinuses occur in 
2-8% of patients94. Late stricture of the ileo-anal anastomosis is reported in 10-
17%35,80. However, a report from the Mayo Clinic showed anastomotic strictures 
in around 40% after 20 years36. The majority of strictures are anastomotic webs 
that can be treated by digital or instrumental (Hegar) dilatation, often in office 
settings. A few patients require more extensive procedures35. Except for 
pouchitis, small bowel obstruction is the most common complication after 
IPAA; the reported incidence varies between 15 and 40%35,36,81. Around 25% of 
the patients need a surgical intervention, but the majority can be managed 
conservatively81.  
Most surgeons advocate a temporary loop ileostomy when performing an 
IPAA95. However, the loop ileostomy itself can be associated with problems. 
There is a readmission rate of 15%, mainly due to dehydration96. Furthermore, 
the closure is associated with complications. Wong et al97 reported a morbidity 
Ulcerative Colitis – Surgery Outcome and Pathophysiological Aspects 
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rate of around 10%, more than half of the morbidity was due to small bowel 
obstruction97. 
Pouchitis  
Pouchitis, inflammation of the ileal reservoir, is the most common long-term 
complication, with a range of 30-50% depending on definition and follow-up 
time38,98,99. Hahnloser et al36 showed that 40% of patients experienced at least 
one episode during the first 10 years after IPAA and the rate increased to 70% 
after 30 years36. The clinical features of pouchitis are similar to those of colitis 
and include frequent emptying of the pouch; the intestinal content is often more 
liquid and sometimes bloody. Faecal urgency, abdominal cramps and fever can 
also occur. At endoscopy, the typical features are erythema, erosions, friability, 
granularity, oedema and sometimes erosions (Fig. X)100,101. Histological 
examination of the pouch mucosa typically shows infiltrates of acute 
inflammatory cells, combined with signs of chronic inflammation100. Most 
patients experience short-lived pouchitis that respond promptly to treatment 
(see below). However, 10-20% develop recurrent, or chronic pouchitis38,99.  
 
Figure X. Endoscopic pictures of ileal pouches with pouchitis. By permission of stomavice.co.uk. 
Etiology 
The etiology of pouchitis is still unknown. However, many theories have 
evolved throughout the years102. Initially, it was believed that fecal stasis with 
bacterial overgrowth was the basic mechanism103, but this theory was later 
abandoned. Some authors have reported an increased bacterial count in patients 
with pouchitis104, while others have not105. Cell turnover and metaplasia of the 
pouch has been observed, turning the ileum to a more colon-like tissue and 
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pouchitis could therefore resemble a ”recurrence of UC”106. An argument 
against this theory is that pouchitis ususally responds to treatment with 
antibiotics107. Another theory is that bile salts, deconjugated by bacteria in the 
ileum, could increase the quantity of secondary bile acids in the pouch. These 
are cytotoxic, increasing the permeability of the pouch mucosa and this process 
could promote pouchitis108,109. Ischaemia of the pelvic pouch mucosa has been 
recorded110 and proposed as a contributing factor to pouchitis. 
Pathophysiological mechanisms include potential production of free radicals, 
with secondary inflammation111.  
Some risk factors for development of chronic pouchitis have been proposed. 
These include back-wash ileitis112, extensive colitis113, primary sclerosing 
cholangitis (PSC, see below)112, and use of non-steroidal anti-inflammatory 
drugs (NSAIDs)114. 
Diagnosis  
The diagnosis of pouchitis should ideally be based on clinical, endoscopical and 
histological findings. The most well known tool for diagnosis is the Pouchitis 
Disease Activity Index (PDAI)100. This score includes three subscores: clinical 
symptoms, endoscopic findings, and histological changes100. Prompt response to 
treatment with antibiotics (below), together with clinical symptoms is regularly 
taken as diagnostic of pouchitis in clinical practice101. However, the risk with 
this empirical approach is that the incidence is overestimated101. 
Treatment  
First-line therapy in patients with acute pouchitis is antibiotics. The majority of 
patients will have symptomatic relief in 1 to 2 days107, and one to two weeks 
treatment is usually enough to achieve remission. Historically, Metronidazol has 
been the first choice107,115,116 and it appears to be effective in 80-90%117. More 
recently, Ciprofloxacin has become more commonly used118. Metronidazol and 
Ciprofloxacin can be used in combination when monotherapy is insufficient119. 
However, some patients (10-20%) may require maintenance therapy with 
ongoing antibiotic treatment, either in low dose or at a reduced frequency120.  
Budenoside, cortocosteroids, sulphasalazine and 5-ASA have all been used in 
acute pouchitis, but not at long-term120-122. Infliximab has been used in chronic 
pouchitis123-125. However, patients included in the studys are few and long-term 
results are still lacking. Probiotics (VSL#3, a mixture of eight strains of 
probiotics) have been shown to be effective as matintenance therapy (antbiotics 
used to induce remission) and primary prophylaxis117,126.  
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Still, the therapy of pouchitis remains mainly empiric. Randomized, multicentre, 
placebo-controlled, double-blinded, dose-ranging studies are warranted127.  
Pouch Failure 
Failure of the pouch is defined as excision or diversion of the pouch, the latter 
varying in different studies from 1/2 to 2 years of time35,36,128-130. Failure rates 
varies among studies, but are usually around 5-7% at 5 years and 8-10% at 10 
years39,128,131,132 in patients with confirmed UC. In unselected cohorts, also 
including patients with CD and indeterminate colitis, the failure rate increases to 
around 35% after 10 years133,134. In cases where a secondary loop ileostomy is 
performed, the failure rate increases considerably (to around 65%)135. If the 
pouch has been defunctioned for more than one year, it is rarely reversed136.  
The most common reason for pouch failure is a septic complication (fistula, see 
also Complications above)35,129,130,137. Another common reason for failure is 
poor function (other reasons ruled out)137,138. Chronic pouchitis however, is a 
quite rare reason for failure (around 10%)137.  
In a retrospective study139 including almost 2000 patients, four pre- and four 
postoperative factors were identified to be associated with pouch failure. 
Preoperative factors were: diagnosis, comorbidity, anal pathology and poor 
outcome of anal sphincter manometry. Postoperative factors were: anastomotic 
separation, anastomotic stricture, pelvic sepsis and fistula. The predictive risk 
for pouch failure at 1, 5 and 10 years was 0.1, 0.4 and 0.8%, respectively, in 
patients without risk factors. In patients with 6 risk factors however, the 
predicitve risk was estimated to 30, 70 and 90 %139. 
Pouch Function 
Pouch function is a complex composite variable and can be considered the 
summary of several factors (anal sphincter function, pouch volume, pouch 
compliance, pouch emptying, small bowel function, pelvic volume, prescence of 
irritated bowel syndrome, psychological factors)140. In the literature, functional 
scores often evaluate the pouch function36,129,141-144. The scores can be used in 
clinical practice and usually include items associated with QoL36,128,141,145 (see 
also Methods). Pouch function has been evaluated in individual patients over 
time and it seems to be stable, or marginally deteriorated146. Pouch function also 
correlates to HQoL128,144. 
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Pouch Physiology 
Manovolumetry is a commonly used method for evaluation of pouch physiology 
(i.e. anal pressures and pouch volume/compliance)143. The major contributor to 
anal continence is the anal sphincter complex. The internal sphincter is a 
smooth muscle that contributes considerably to the anal resting pressure. It 
provides for passive continence and reduced resting pressure can be associated 
with leakage and soiling140. The voluntary control depends on the external 
sphincter muscle, the puborectalis muscle and the striated pelvic floor muscles. 
IPAA surgery regularly leads to reduction in anal pressure; some recovery is 
seen over time, however, usually not to preoperative levels147-149.  
Pouch volume and pouch compliance have been observed to affect pouch 
function; large pouch volume and high compliance leads to a lower bowel 
movement frequency and hence, a better functional outcome143,150,151. Reported 
volumes of the IPAA:s differ between studies with a range from around 15061 to 
around 300 ml152. It has been proposed that pouch volume is the most 
important determinant for pouch function143. However, only around 20% of the 
variability of the functional score can be explained by volume and pouch 
compliance143. Some data indicate that compliance and volume is greater in 
pouches with W -design, compared to those with S - and J-design61. Interestingly, 
a recent study in patients with pouch dysfuncion suggested that compliance was 
not a contributing factor to the clinical problem153. 
From Dysplasia to Carcinoma  
 
Malignancy develops by a multistep process, during which the normal cell 
progresses subsequently to a premalignant state (low-grade and high-grade 
dysplasia), carcinoma in situ, and further to carcinoma154. This is a multistep 
process associated with, and depending upon, defects in genetic controlling of 
normal cell proliferation and death155. Genomic instability leads to the 
generation of single and multiple aneuploid populations of cells. By further 
genetic changes, these populations eventually acquires the capacity for 
invasion156. 
In some diseases in the gastrointestinal tract, the axis inflammation-dysplasia-
carcinoma is more or less evident. These include: esophagitis-Barret´s 
esophagus-esophageal carcinoma157, primary sclerosing cholangitis-dysplasia-
cholangiocarcinoma158, ulcerative colitis-dysplasia-colonic carcinoma (Fig. 
XI)159,160.  
The cumulative incidence of dysplasia in UC varies between studies; one study 
showed 6% after median 20 years161, while another showed 23.5% after 10 
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years162. The cumulative probability of carcinoma has been estimated to be 2% 
at 10 years, 8% at 20 years and 18% at 30 years163.  
Indefinite for dysplasia (IFD) is defined as cytoarchitectural alterations, 
including a spectrum of inflammatory and non-inflammatory changes, that do 
not reach the pathologists threshold for an unequivocal diagnos of true 
dysplasia (LGD or HGD)164. The clinical importance and outcome of IFD 
remains to be definied165 (see below, Results and Comments, dysplasia). 
 
 
 
Figure XI. Light microscopy of biopsies from patients with ulcerative colitis and low-grade 
dysplasia (LGD), high-grade dysplasia (HGD) or invasive carcinoma. In LGD there is a loss of 
mucus content in epithelial cells and some nuclear atypia (arrow). In HGD there is a more 
prominent nuclear atypia (arrow) and a marked loss of tissue architecture. When invasive cancer is 
diagnosed, cells or glandular structures are invading the underlying tissue (arrow) and there is a 
marked cellular and structural atypia (arrowhead). 
Histopathology and Neoplasia in IPAA 
The assumed mechanisms for neoplasias (dysplasia or carcinoma) occurring in 
IPAA:s are based on the assumption that the axis chronic inflammation-
dysplasia-carcinoma, can be applied159. In this context, it seems important to 
emphasize that the IPAA contains two different tissues: small bowel mucosa in 
the ileal pouch and rectal mucosa in the ATZ70,166. The inflammation-neoplasia 
axis can be adopted considering the ATZ139,140,159,160. However, the pathogenesis 
of neoplasias occuring in the ileal pouch is less clear. To date, 77 cases with 
dysplasia and 42 with carcinomas in IPAA:s, have been reported29.  
 
 
Proposed Risk Factors for Neoplasia in the IPAA.  
 
Several factors have been purported to be associated with an increased risk for 
neoplasia in the IPAA. These include: 
 
1) Previous dysplasia or carcinoma in resected specimen29,70,72,73,167,168  
 
is suggested to be the most important risk factor29,72,168,169 and in recent studies 
actually outpointed as the only one72,73. In the large study by Kariv et al72, the 
Mattias Block 
 
16 
adjusted hazard ratio for neoplasia was 3.62 (95% CI, 1.59-8.23) between 
patients with neoplasia in their specimen, versus patients without; 3.76 (95% CI, 
1.39-10.19) was obtained in a similar study by Derikx et al73. Considering the 
ATZ, one study estimated the risk for neoplasia to be around 10% when 
dysplasia is present in the resected specimen and around 25% in cases with 
carcinoma, after a follow-up time of median 3 years167.  
 
2) Concurrent PSC170-172 
 
Patients with IBD-PSC have an increased risk for neoplasia in the large bowel 
before colectomy171. Furthermore, it has been proposed that patients with UC-
PSC have a higher risk for development of mucosal atrophy and neoplasia in the 
ileal pouch, compared to patients with UC-only170. Other studies have not been 
able to confirm these data72,73.  
 
3) Chronic pouchitis/type C mucosal changes in the ileal pouch173 
 
In a large study from the Cleveland Clinic, chronic pouchitis was evaluated as a 
potential risk factor for neoplasia72. The adjusted hazard ratio obtained was 0.81 
(0.28-2.31); thus, it seems unlikely that chronic pouchits is an independent risk 
factor.  
 
4) Long duration of UC172 
Longstanding colitis (10-20 years) has been proposed as an undependent risk 
factor172. Interestingly, in a study on 26 patients with carcinoma in IPAA:s, all 
patients had a disease history of 10 years, or more29. However, Kariv et al did 
not identify duration of UC as an independent risk factor (adjusted hazard ratio 
1.01 [0.97-1.05])72. 
Dysplasia in the Ileal Pouch: 
Until now, 77 cases of dysplasia in the IPAA have been reported29; 49 were 
LGD, 15 HGD and 13 unspecified dysplasia. The locations were 28 (36%) in 
the pouch body, 6 (8%) in an unspecified location in the pouch and 2 (3%) at 
both ATZ and in the pouch. (ATZ was the location in 41 (53%)29 cases, see 
below.) Different rates of prevalence for dysplasia in the pouch have been 
reported by different authors, from low prevalences (0.6%-0.9%)72,73,174,175 to 
higher ones (7.5%-19%)170,176,177 (See Table 1). 
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Table 1. Cases with dysplasia in the ileal pouch (2000-). 
 
Reference No Duration 
IBD, y 
Duration 
follow-up, y 
Dysplasia [n] Prevalence 
Thompson- 
Fawcett 
2001175 
106 
 
NA 2-22 1 LGD 0.9% 
Hultén  
2002176 
40 CI NA 26-34 
med 30 
3/2 LGD* 7.5%/5%* 
Herline  
2003174 
160 NA 4-13 1 LGD 0.6% 
Stahlberg 
2003170 
16 
PSC 
9-13 4-20 3 LGD, 
1 HGD 
LGD 19% 
HGD 6% 
Börjesson 
2004177 
45 1-28 
med 6 
17-46 
med 25 
2/0 LGD* 4.5%/0* 
Elkowitz  
2004178 
30 0.5-21 
med 3 
1-5 
med 3 
2 aneuploidy 6.7% 
Hernandez 
2010179 
38 1-11 3, 6 and 12 
mo post-op 
1 LGD 2.6% 
y, years; NA, not available; med, median; mo, months; post-op, postoperative. 
* Two independent pathologists. 
 
Dysplasia in the ATZ 
 
It should be emphasised that the proctocolectomy preceeding the IPAA 
substantially reduces the risk for UC-associated neoplasia. However, the 
procedure does not completely void the risk. When a stapled anastomosis is 
employed, there is a cuff of rectal mucosa (0.5-2 cm) left behind; this tissue of 
mucosa has the potential to develop inflammation and neoplasia70. In a hand-
sewn anastomosis, preceeded by mucosectomy, remnants of rectal mucosa 
(islets) have been found in as much as 20% of the cases180,181. Among 77 reports 
of dysplasia in IPAA, the location was ATZ in 41 (53%)29. As for the pouch, the 
prevalences varies between studies, from 0%-0.7%72,73,182,183 to 2.9%-
3.4%70,178,184 (See Table 2). 
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Table 2. Cases with dysplasia in the ATZ (2000-). 
 
Reference No Duration 
IBD, y  
Duration 
follow-up, y 
Dysplasia Prevalence 
Thompson- 
Fawcett 
2000185 
113 0.3-40  
med 7 
0-10   
med 2.5  
1 aneuploidy 0.9% 
O´Riordian 
2000184 
210 0.2-38  
med 7  
5-10  
med 6.5  
6 LGD 
1 HGD 
LGD 2.9% 
HGD 0.5% 
Remzi 
200370 
178 NA 12-13  
med 10.8  
6 LGD 
2 HGD 
LGD 3.4% 
HGD 1.1% 
Coull 
2003182 
110 2-32  
med 9  
1-12 
med 4.5  
0 0 
Saigusa 
2003183 
91 0.3-42  
med 10 
0.2-9  
med 3 
0 0 
Pishori 
2004186 
303 0.2-18  
med 9 
med 3.5 2 dysplasia 0.7% 
Elkowitz  
2004178 
30 0.5-21  
med 3 
1-5  
med 3 
1 aneuploidy 3.3% 
y, years; NA, not available; med, median 
 
Carcinomas in IPAA 
Until recently, 42 cases with carcinomas in IPAA:s have been reported29; 11 
were reported from the same group72. Eight (19%) cases have been found in the 
pouch body, 4 (10%) in unspecified location of the pouch, 1 (2%) in the afferent 
limb and finally, 2 (5%) in the ATZ and pouch body together. However, the 
majority (27; 64%) was localised in the ATZ only29. Furthermore, in the recent 
nationwide study from Holland, the majority of carcinomas (10/16; 63%) was in 
the ATZ73. Interestingly, the literature reveals that the majority of patients with 
carcinomas actually had mucosectomy and hand-sewn anastomosis. The reasons 
for this could be length of follow-up (all anastomoses were hand-sewn in the 
beginning of IPAA surgery)187 and that hand-sewn anastomoses preferentially 
were performed in patients with risk factors169. 
 
Surveillance for Neoplasia in IPAA  
 
Although the cases of carcinomas in IPAA:s are few, the reports have started a 
discussion on the place for surveillance72,73,188. Recent guidelines from the 
European Crohn´s and Colitis Organisation (ECCO) suggest surveillance for 
patients with neoplasia in the (procto)colectomy specimen and for patients with 
PSC188.  
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Primary Sclerosing Cholangitis (PSC) 
First described by Smith and Loe189, primary sclerosing cholangitis (PSC) is a 
chronic, progressive inflammatory disease in the biliary tree, associated with 
formation of strictures, fibrosis and destruction of intra and/or extrahepatic bile 
ducts190. PSC can deteriorate liver-function and lead to end-stage liver 
disease190,191. The specific ethiology of PSC is unknown, interactions between 
environmental factors and genetic variations are components of theories 
regularly proposed192. 
PSC affects males more than females (2:1). The incidence is 0.9-1.3/100 000 
person-years and the prevalence is 8.5-13.5/100 000193,194. A recent study from 
the western health care region (Västra Götaland), Sweden, showed a prevalence 
of 16/100 000 person-year195. Interestingly, this is the highest prevalence 
reported to date. 
The clinical course of PSC in a single patient is difficult to predict and can vary 
from asymptomatic disease to fulminant cirrhosis and liver failure196. The most 
feared complication is cholangiocarcinoma196. There is no medical treatment for 
PSC and the only curative treatment is liver transplantation191,196.  
 
PSC is associated with UC in up to 75 % of patients in Northern Europe190,197 
and around 5% of patients with UC will develop PSC198. In concordance with 
UC, PSC does not seem to be a classic autoimmune disease. The association 
between PSC and UC is not fully understood199. Interestingly, similar as for UC, 
smoking has a protective effect on PSC192,200. 
 
Surgery for UC in Patients with PSC 
 
It is important to be aware of that (procto)colectomy does not affect the 
progression of the liver disease201. The course of colitis in patients with UC and 
PSC (UC-PSC) is different from that in patients with UC without PSC (UC-
only). Patients with UC-PSC usually have a more quiescent clinical course, 
increased incidence of pancolitis and a higher risk for dysplasia and 
carcinoma202,203. As a consequence, the prerequisites for surgical treatment differ 
from those for patients with UC-only. Patients with UC-PSC have a higher rate 
of colectomy204, dysplasia and carcinoma are more common indications171.  
 
Surgical options for patients with UC-PSC are basically the same as for patients 
with UC-only. However, for the vast majority of patients with UC-PSC, IPAA is 
going to be advocated205,206. Proctocolectomy and ileostomy can be associated 
with massive bleedings from peristomal veins/varices (in around 25% of 
patients)205, a complication very diffcult to treat205,207. The use of IRA in UC has 
increased (in Scandinavia) over the last decades; however, the literature on 
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patients with UC-PSC and IRA is sparse. Although IPAA is the preferred 
choice, several studies have found that patients with UC-PSC are at a higher risk 
for development of pouchitis205,208-210, while others did not211,212. 
 
Few studies have reported on functional results after IPAA in patients with UC-
PSC; however, the outcome seems to be similar to patients with UC-
only206,211,213. Interestingly, there is no study on QoL after colorectal surgery for 
patients with UC-PSC.  
Galectins-Potential Role in the Pathophysiology of UC 
As described above, the pathophysiology of UC is very complex and essentially 
unknown. Since UC is characterized by an inflammatory process, it is of interest 
to explore different factors that contribute to the regulation of the inflammatory 
process. One such factor is the mammalian galectin. Galectins are a family of 
small soluble carbohydrate-binding proteins (lectins) that participate in a large 
number of biological processes such as development and progression of 
carcinoma214,215 as well as immunoregulatory effects215,216. For these reasons, 
galectins represent potential targets for therapeutic intervention of disease217-219. 
Galectins contain a conserved carbohydrate recognition domain (CRD) 
composed of 135 amino acid residues with affinity for β-galactosides as found in 
glycoproteins and glycolipids220. They are synthesized in the cytosol and have 
functions intracellularly (cytosol and nucleus) as well as in extracellular 
compartments (cell-cell and cell-matrix adhesion, regulating cell survival and 
signalling, cell differentation, influencing chemotaxis, or interfering with 
cytokine secretion affecting the immune regulation)221,222. Galectins interact with 
carbohydrates wich exist in different forms on almost all cell-surfaces. Also the 
extracellular matrix (ECM) contains large amounts of carbohydrates, mainly 
glycoproteins223. Carbohydrates are involved in many biological processes, and 
play potential important roles in several 
disorders and diseases223,224. The ability of 
galectin CRDs to cross-link the lactoseamine 
unit (carbohydrate + amino acid) within surface 
glycoreceptors allows galectins to participate in 
several immune responses220.  
The mammalian galectin family consists of 15 
proteins and are subdived into three subgroups 
depending on the protein architecture; i) the 
prototype galectins (galectins-1, -2, -5, -7, -10, -
11, -13, -14 and -15), containing one CRD wich 
can occur as monomers or as dimers, ii) 
Figure XII. Galectins-1 to -4. 
From Leffler et al. 
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chimera-type galectins (galectin-3), wich contains one CRD and one non-lectin 
N-terminal domain, occuring as monomers, dimers, or higher order oligomers 
and iii) the tandem repeat-type galectins (galectin-4, -6, -8, -9 and -12), 
containing two distinct CRDs connected by a short linker region220,225. See 
Figure XII. 
Galectins 1-4 in the Gastrointestinal Tract  
Nine galectins (-1, -2, -3, -4, -6, -7, -8, -9, and -15) are expressed in the mammal 
digestive tract. Galectins-1 to -4 have all been observed within the human 
gastrointestinal tract, both in the normal digestive tract226 as well as in the 
diseased intestine226-228. Galectins-1 and -2 are evolutionary related paralogues of 
a prototype galectin229. The most prominent galectins in the intestinal epithelial 
cells are galectins-3 and -4. Figures XIII-XIV shows the expression patterns of 
galectins 2-4 in normal and inflamed colonic tissue, below are the distribution 
and function of different galectins described more in detail. 
 
Figure XIII. Expression of galectin-2, -3 and -4 in normal colon tissue. 
 
 
 
Figure XIV. Expression of galectin-2, -3 and -4 in inflamed colonic tissue. Galectins -2 and -3 
stain the entire cytoplasm when the epithelial cells are devoid of mucose. Galectin-4 is only 
present in a supranuclear position. 
 
Galec t in -1  is mainly anti-inflammatory by induction of apoptosis in T-cells 
responsible for production of IFN-g227,230. Galectin-1 contributes to activation 
of B-cells231 but can, in contrast, negatively regulates B-cell proliferation and it´s 
signal transduction232. Galectin-1 also affects the physiology of monocytes and 
Mattias Block 
 
22 
macrophages through effects on antigen presentation and phagocytosis233. In 
colonic carcinoma, increased expression of galectin-1 has been associated with 
neoplastic progression224,234.  
Galec t in -2  has been studied less but found mainly to be anti-inflammatory and 
supporting wound healing in the intestine235-237. The mechanism is induction of 
apoptosis of activated T-cells238 and inhibition of pro-inflammatory cytokines 
release (IL-6, IL-12p70)237.  
The most thouroughly studied galectin in humans is ga l e c t in -3 , first defined as a 
surface marker on macrophages239, then been found in many cell types, 
including eosiniphils, lymphocytes, mast cells, neutrophils and activated 
epithelial cells240. Galectin-3 is highly expressed in macrophages and is mainly 
pro-inflammatory, promoting neutrophil and monocyte adhesion to laminin and 
endothelial cells241, but has also regulatory and tissue protecting effects220. 
Down-regulation of galectin-3 in intestinal epithelium in IBD has been 
reported228, possibly involved in the induction of fibrosis. Galectin-3 is used in 
clinical histopathology, particularly in diagnosing thyroid tumors242. Increased 
level of galectin-3 has been observed in colonic carcinoma and correlates with 
neoplastic progression224,243-245.  
Galec t in -4  is highly and specifically expressed in intestinal epithelial cells246. In 
IBD, galectin-4 has the most distinct pathogenic role as a specific activator of 
intestinal CD4+ T-cells247, stimulating IL-6 production, an inflammatory 
cytokine contributing to progression of colitis. Increased expression of galectin-
4 has been observed in colorectal carcinoma, suggesting a prognostic value for 
galectin-4234. 
Studies on Galectins in IBD  
Various aspects for the roles of galectins in IBD pathogenesis (as well as in 
colorectal adenoma/carcinoma) have been studied, see Table 3. Most of these 
have been studied in various experimental animal models227, both pro- and anti-
inflammatory properties of various galectins have been identified228,235,236,248. 
Previous studies have implicated galectins in patients with IBD as potential 
markers of disease as well as potential theurapeutic agents230,249. However, the 
clinical significance in the human situation is uncertain. Previous studies on 
humans are limited regarding the number of patients included and their clinical 
status250,251. 
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Table 3. Galectins studied in the human gastrointestinal tract. 
 
Galectin Disease Alteration Clinical 
implication 
Refs 
1 Colorectal 
adenoma and 
carcinoma 
 
IBD 
Increased 
expression 
 
 
Increased 
expression and 
high IL-10 
Prognostic value 
 
 
 
Possible treatment 
224,234,243 
 
 
 
230,249 
2 IBD Increased 
expression 
Supress 
inflammation 
235,237 
3 Colorectal 
adenoma and 
carcinoma 
 
 
 
IBD 
Increased 
expression 
 
Decreased 
expression 
 
Increased and 
decreased 
expression 
Prognostic value, 
clinical stage 
 
Metastatic 
capability 
 
Pro- and anti-
inflammatory 
Fibrosis 
224,243-245 
 
 
252 
 
 
228,240,253,254 
4 Colorectal 
carcinoma 
 
IBD 
Increased 
expression 
 
Increased 
expression 
Prognostic value 
 
 
Enhance 
inflammation 
234 
 
 
247 
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AIM 
 
Ulcerative Colitis is a complex disease, often with onset at young age. A deeper 
understanding of the pathophysiology, clinical course and treatment strategies is 
crucial for optimal care of patients. The overall objective of this thesis was to 
further extend the knowledge in the area of pathophysiology and the outcome 
of surgery.  
 
The specific aims of the included studies were to investigate: 
 
 
• Outcome of different IPAA-designs on long-term IPAA function (I). 
 
• The frequency of neoplasia in patients with IPAA and foregoing 
neoplasia in their colorectal specimen (II).  
 
• Outcome of IPAA and IRA in patients with UC and concurrent PSC 
(III).  
 
• If the galectin expression in the colonic intestinal epithelium correlates 
to the severity of the inflammatory response (IV). 
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PATIENTS 
 
Paper I 
This study included 619 patients from the Swedish Surgery for Colitis Register, 
operated on at Sahlgrenska University Hospital 1982 – 2004. All patients had 
IPAA. Five hundred and fifty-six patients had either J- or K -pouch and were 
included in the study. Four hundred and twelve (87%) returned the 
questionnaire. 
Paper II 
Six hundred and twenty-nine patients from the Swedish Surgery for Colitis 
Register were operated on with IPAA in Gothenburg, 1982 – 2010. Patients 
with dysplasia or carcinoma in their colorectal specimen were identified. Ninety 
patients were included in the study, 56 completed the study protocol.  
Paper III 
The study group (UC-PSC) comprised patients with UC and PSC from the PSC 
database, Rikshospitalet, Oslo, Norway. All patients (n=48) had colectomy or 
proctocolectomy and subsequently IPAA (n=31) or IRA (n=17).  
The control group (UC-only) was recruited from the Swedish Surgery for Colitis 
Register; all patients (with UC, but without PSC) were operated on at 
Sahlgrenska University Hospital, Gothenburg. One hundred and thirteen (62 
IPAA and 51 IRA) patients were included. Patients with IPAA (in ratio 2:1 to 
the study group), with similar age at colectomy and the same gender as the 
patients with IPAA in the study group, were randomly chosen as controls. For 
patients with IRA, 57 consecutive patients, operated during the same time frame 
(1995–2007) as the patients in the study group, were included. Two patients had 
emigrated, leaving 55 available for analysis.  
Paper IV 
Twenty-two (14 males, 8 females) patients with UC, scheduled for bowel 
resection, were included prospectively. Ten patients (8 right-sided 
hemicolectomies for colonic carcinoma, 2 sigmoid resections for volvulus) were 
enrolled as controls.  
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METHODOLOGICAL CONSIDERATIONS 
 
Swedish Surgery for Colitis Register (I, II, III) 
Since 1982, consecutive data on patients operated on with IPAA at Sahlgrenska 
University Hospital, Gothenburg have been registered. The Register includes 
patient demographics, diagnoses (UC or CD), data on surgical procedures, 
histopathology, functional outcome, complications, and failure. Patients with 
IRA are included since 1995. The Register is now part of The Swedish IBD 
Registry – SWIBREG, wich today includes around 23 000 patients. The register 
has been validated regularly throughout the years.  
The Norwegian PSC Register (III)  
The Norwegian PSC Register is a database that contains data on around 450 
patients with PSC admitted to the Section for Gastroenterology, Oslo University 
Hospital, Rikshospitalet, Oslo, Norway. The register includes all PSC-patients 
from the Oslo area, but also patients who were referred from all over Norway. 
Since the department is the only liver transplant centre in Norway, all 
Norwegian patients evaluated for liver transplantation, are included in the 
Register.  
 
Pouch Functional Score (Öresland score; I, III) 
 
Pouch function was assessed with a score that was developed and has been 
extensively used in our institution for more than 20 years255. The score includes 
10 items, summarized to a score (0-15, 15 worst). 
In an attempt to validate the score, 60 patients completed the score-
questionnaire, and plotted their self-experienced function on a visual-analogue 
scale. The correlation between the two recordings was r=0.55, p<0.001. The 
patients had a tendency to grade better on the VAS-scale than on the Öresland 
score256. Another study from our institution showed that a score>8 is correlated 
to a reduced HQoL128. 
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Table 4. Öresland score (Pouch Functional score) 
 
Score items Score points 
      0 1 2 
No of bowel movements    Day 
                                           Night 
≤4 
0 
5 
>1/week 
≥6 
≥2/night 
Urgency No Yes   
Evacuation difficulties No Yes   
Soiling, seepage                   Day 
                                           Night 
No 
No 
>1/week 
>1/week 
 
Perianal soreness No Occasional Permanent 
Protective pad                     Day 
                                           Night 
No 
No 
>1/week 
>1/week 
 
Dietary restrictions No Yes  
Medications No Yes  
Social handicap No Yes  
 
Throughout the years, several scores for evaluation of IPAA function have been 
proposed. Lovegrove et al developed a score, PFS (Pouch Functional Score), 
with items only related to HQoL (Cleveland Global Quality of Life)144. Each 
item was given a weight that correlated to the impact on HQoL. Several of the 
included items are similar to the ones in the Öresland score (bowel frequency, 
grade of incontinence, urgency, and use of medication). However, some items 
are not included in the PFS (evacuation difficulties, perianal soreness, diet and 
social restrictions)144.  
In a recent study from Aarhus, Denmark142, a score including 13 items, was 
proposed. The score is similar to the Öresland score, but also includes stool 
concistency, incomplete evacuation and need for antibiotic treatment. The score 
does not include social handicap, but has been correlated with QoL in a 
multivariate model142. Urgency, incomplete emptying, number of bowel 
movements/24 hours, major incontinence and use of anti-diarrhoeal 
mediciation was found to have a significant impact on QoL142. The score was 
subsequently used in a study on all patients (1047) in Denmark, operated on 
with IPAA for UC 1980-2010257. 
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Rectal Function (III) 
 
Rectal function was evaluated by the Öresland score. As written above, the 
score is tailored for patients with IPAA, but has been used before for evaluation 
of patients with IRA for UC40.  
 
Endoscopy & Biopsy (II) 
 
Olympus video-gastroscopes were used for macroscopic evaluation and mucosal 
biopsies of the ileal pouches. The pouch mucosa was evaluated according to 
PDAI100 and included assessment of edema, friability, granularity, loss of 
vascular pattern, edema, polyps, lesions and ulcerations. A rigid pediatric 
anoscope was used for evaluation and biopsies at the ATZ. 
The majority of the examinations were conducted by the same investigator 
(MB). Four biopsies were collected from each pouch and two from the ATZ. 
Collecting biopsies from the ileal pouch is a relatively straight forward 
procedure. In the ATZ however, the manoeuvre is technically demanding and 
often associated with a considerable discomfort for the patient, especially in 
patiens with hand-sewn anastomoses69.  
Where and how biopsies from the IPAA should be collected depends on the 
aim of the procedure. ECCO guidelines for surveillance do not provide further 
details. Four to 6 biopsies from the ATZ and 2 to 6 from the pouch body and 
afferent limb have been suggested 29. 
 
Histopathology (II, IV) 
 
In paper  II , the biopsies were fixed in formalin, embedded in paraffin after 
dehydration and cut at a thickness of 3-4 µ, stained with haematoxylin-eosin and 
in addition PAS to illustrate mucins. Biopsies from the ileal pouches were 
reviewed according to established criterias for mucosal adaptation, 
chronic/acute inflammation258 and dysplasia259. Biopsies from the ATZ:s were 
reviewed for chronic inflammation258 and dysplasia259. Dysplasia was graded as 
no dysplasia, indefinite for dysplasia (IFD), low-grade dysplasia (LGD) and 
high-grade dysplasia (HGD)259. There are well-known difficulties and 
controversies about the evaluation of dysplasia in the presence of 
inflammation173,176,259-262. A wide interobserver variation has been found between 
pathologists260,261,263 and the consistency appears to be poor, especially in 
grading of IFD and LGD150,176,73,165,260. In a recent study by Derikx et al, a 
histopathologic reassessement of 29 cases was performed; 22 (76%) cases 
shifted grad (18 were downgraded and 4 upgraded)73. Therefore, two 
experienced pathologists with special interest in the gastrointestinal tract 
reviewed the biopsies independently. 
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In paper  IV , the colorectal specimens were collected at regular intervals 
according to a standardized protocol from each colonic and rectal area. In 
addition, specimens were collected separately from macroscopic lesions and 
ulcerations areas, if present. The specimens were fixated in formalin and 
embedded in paraffin. Inflammation grade was evaluated after staining with 
haematoxylin-eosin. The inflammatory activity was graded as mild (cryptitis), 
moderate (crypt abscesses) or severe (ulcerations). Leukocyte subtypes were 
identified by morphology (neutrophilic granulocytes and lymphocytes) and, in 
addition, by cell-specific monoclonal antibodies; CD3 (T-cells), CD68 
(macrophages) and CD138 (plasma cells). 
Pouchitis Disease Activity Index (PDAI; III) 
 
PDAI is the most well known score for grading of pouchitis. This 18-point 
score was developed by Sandborn et al in 1994100 and consists of a triad 
domains: 1) clinical symptoms, 2) endoscopic findings and 3) histological 
changes. Each subscore ranges from 0-6 (6 worst), with a maximum summoned 
score of 18.  
Another widespread classification of pouchitis is Moskowitz (St Marks) 
criteria258. The score consist of histopathological gradings only and scores acute 
inflammation (0-6) and chronic inflammation (0-6). Thus, PDAI only evaluates 
acute inflammation (PMN infiltrates and ulcerations), whereas Moskowitz258 
also evaluates chronic inflammation (inflammatory infiltrates [lymphocytes] and 
villous atrophy). Some authors recommend that studies refer to both indices264.  
Yet another score that evaluates chronic inflammatory changes is the Heidelberg 
score265. The Heidelberg score and the PDAI score were validated in 41 
patients265. Considering both scores, there seem to be a low correlation between 
the symptom sub-score and endoscopy/histopathlogy. Therefore, it was 
proposed that pouchitis could be diagnosed only by endoscopy and 
histopathology (omitting the symptom component)266. Others however, have 
proposed that the histopathological component should be left out101. Several 
studies use a clinical definition (usually typical symtoms and/or prompt 
response to antibiotic treatment) of pouchitis208,209,212.  
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Proctitis (III) 
In patients with UC-PSC and IRA, proctitits was recorded at scheduled follow-
up visits that included endoscopy of the rectum with a flexible endoscope; one 
endoscopist evaluated all patients. The macroscopic appearance of the mucosa 
was graded according to the Mayo score267. Six biopsies were taken from each 
patient. Histopathological inflammation was graded according to established 
criteria268 (absent, mild, moderate or severe)268.  
Surgical Complications after IPAA or IRA (III) 
Surgical complications were defined as any complication after IPAA or IRA 
demanding an endoscopic or surgical intervention. Recorded complications 
were: bleeding, anastomotic dehiscence, anastomotic stricture, small bowel 
obstruction, pelvic sepsis, or fistula. In patients with UC-PSC, complications 
were registered prospectively during scheduled follow-up visits. In patients with 
UC-only, complicatons were recorded by data from the Swedish Surgery for 
Colitis Register and from review of medical records.  
The analysis of patients with UC-only has weaknesses since a valid retrospective 
recording of surgical complications is difficult to achieve. However, the items 
(associated with an endoscopic or surgical intervention) selected for analysis in 
the study were robustly addressed in the patients’ medical records. The most 
validated method to record surgical complications is Clavien-Dindo grading 
system269. The score is divided into 7 groups ranging from any deviation to 
intervention under anesthesia, life-threatening complication, failure and 
eventually death269. 
Failure of IPAA or IRA (III) 
Failure of the IPAA was defined as excision of the pouch or diversion with a 
proximal stoma for more than one year36,129,131,137. Failure of the IRA was 
defined as proctectomy or diversion for more than one year40,52,54. The main 
reason (according to the Register/medical records) for failure was recorded.  
 
Immunohistochemistry (IV) 
 
We used an automated immunohistochemical staining method, the EnVision™ 
Flex high pH (Link) detection kit (Dako K8000, Copenhagen, Denmark). This 
is a common technique in modern pathology, using immunohistochemistry as a 
diagnostic tool. It is used both in clinical practise and in research. For principal 
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steps of the technique, see Fig. XV. All specimens were coded. Specimens were 
analysed in a blinded fashion by two investigators. Galectin-1, -2, -3 and -4 
expressions were examined and staining intensity was recorded on a 4-level 
scale; negative (0), trace amounts (1), weakly positive (2) and strongly positive 
(3). Focal pattern was assigned as focal (f). The intensity was analysed in 
different areas of inflammatory activity as well as in control tissue. 
 
 
Figure XV A-D. Principal steps of immunohistochemistry. A) Monoclonal antibodies from mice 
(yellow) binds to a galectin antigen (green). B) Large polymers with secondary antibodies (rabbit, 
anti-mice; purple) together with an enzyme (HRP) are added. C) A substrate (diaminobenzidin; 
brown dots) is added. D) The substrate binds in to the enzyme (HRP), resulting in a brown-black 
staining of the specimen, showing the presence and location of the galectin molecule. 
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Statistical Considerations  
Mainly non-parametric methods were employed throughout this thesis. Values are presented 
as median (range) and means (standard deviation). Continous variables were analysed using 
the Mann-Whitney U test, Kruskal-Wallis one-way ANOVA (with post hoc Scheffé test). 
Categorical data were analysed with Fischer´s exact test and χ2 test. Regression analysis 
(univariable and stepwise) was used to identify significant predictors (I, III). Confidence 
intervals for proportions were calculated using normal approximation, and 
kappa statistics were performed to measure interobserver variability in the 
grading of dysplasia (II). P<0.05 was considered statistically significant. The softwares 
used for calculations were Statview® version 5.0.1 (SAS Institute, Berkeley, California, USA) 
(I), SAS for Windows (SAS Institute Inc., Cary, NC, USA) version 9.3 (II) and 
SPSS for Windows software (Chicago, IL, USA) version 19 (III) and 20 (III). 
Ethical Considerations  
 
The Regional Ethical Board at University of Gothenburg (www.epn.se) and the Regional 
Committee for Research Ethics in South Eastern Norway (III) approved the studies.  
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RESULTS AND COMMENTS 
 
Long-term IPAA Function in Patients with 
Different IPAA Designs (I) 
 
Median follow-up time was 13 (1-22) years. Significant differences were 
obtained between K-pouch/hand-sewn (KH)  and J-pouch/hand-sewn (JH) , as 
well as between K-pouch/stapled (KS)  and J-pouch stapled (JS ;  Fig XVI). A 
regression analysis showed that age at surgery and pouch design were significant 
predictors of the Öresland score (p<0.001). 
 
 
Figure XVI. Summarized functional score for included patients. Box plot. JH  (n=96) mean 6.1, 
JS  (27) 6.0, KH  (95) 5.1, KS  (194) 4.8. Horizontal lines within boxes, boxes and errors bars 
represent median values, interquartile ranges and 10th to 90th percentiles respectively. * p=0.002, + 
p=0.034 versus JH ; * p=0.047 versus JS . 
Although the Öresland score is supposed to be a summarized score and not an 
individual score, interesting differences were noted between the groups. 
Evacuation difficulties and use of retarding drugs were significantly more 
common among patients with JS . Moreover, 2/3 of the patients with JH  
suffered from soiling at night; only 1/4 of the patients with KS  reported this 
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problem. Use of protective pads was most common in the JH  group. Compared 
to patients with KS , significantly more patients with JH  had scores ≥ 8. 
Comments 
The obvious weakness of this study is that it is non-randomised. However, 
follow-up time of all groups is long; furthermore, relatively few surgeons 
performed all four combinations of pouches and anastomoses during the study 
period. The response rate is high (87%) and a substantial number of patients are 
included. The K -pouch with stapled anastomosis gives the best long-term 
functional outcome. However, the clinical relevance is not clear.   
IPAA function is a complex parameter (see Introduction). Surgeons can 
probably affect the functional outcome by performing meticulous surgery, with 
nerve-sparing technique. Furthermore, two technical aspects have impact on 
functional outcome: 1. Design of the ileal pouch 2. Method for the ileo-anal 
anastomosis. A meta-analysis assessing outcome for J-,  S - and W -pouches in 
1500 patients revealed higher bowel movement frequency, and more use of 
retarding drugs and protective pads in patients with J-pouches compared to 
both S- and W -pouch56. However, the S -pouch was associated with need for 
anal intubation56. Few studies have been done on functional outcome in the 
long-term perspective. The majority of studies report a stable function over 
time36,129.  
 
Neoplasia in the IPAA (II) 
 
The Ileal Pouch: 
 
One of 56 (1.8%; 95%-CI: 0-5.3%) patients showed LGD in the pouch 
recorded by one pathologist. Each pathologist found IFD in 19 versus 20 
patients, respectively. There was full agreement in 45 (80%) patients (14 with 
IFD and 31 without dysplasia; kappa=0.58).  The majority of the patients with 
IFD demonstrated subtotal-total mucosal adaptation, moderate-severe chronic 
inflammation, and a score ≥3 with regards to acute inflammation (Table 5). No 
HGD or carcinoma was found. 
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Table 5. IFD in the pouch and grade of mucosal adaptation, chronic and acute 
inflammation.  
Values are given as n and (%). 
 
Mucosal adaptation 
 
Pathologist 1 
 
IFD/n (%) 
Pathologist 2 
 
IFD/n (%) 
1 5/19 (26) 1/14   (7) 
2 1/15   (7) 4/17 (24) 
3 13/22 (59) 15/25 (60) 
   
Chronic inflammation 
 
Pathologist 1 
 
IFD/n (%) 
Pathologist 2 
 
IFD/n (%) 
1 0/8    (0) 1/16   (6) 
2 7/26 (27) 5/21 (24) 
3 12/22 (55) 14/19 (74) 
   
Acute inflammation 
score 
 
Pathologist 1 
 
IFD/n (%) 
Pathologist 2 
 
IFD/n (%) 
0 0/4     (0) 0/1     (0) 
1 0/12   (0) 0/3     (0) 
2 5/22 (22) 7/27 (26) 
3 10/13 (77) 10/19 (52) 
4 4/5   (80) 3/5   (60) 
5 0/0     (0) 0/0     (0) 
6 0/0     (0) 0         (0) 
 
 
The ATZ: 
 
29/32 patients with stapled anastomosis were analyzed. Remaining 3 patients 
lacked rectal mucosa in their biopsies. None of the pathologists found LGD, 
HGD or carcinoma. Pathologist 1 recorded two patients with IFD, pathologist 
2 recorded four (kappa=0.31). The majority of the patients with IFD had 
moderate or severe inflammation. See Table 6. 
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Table 6. IFD and grade of chronic inflammation in the ATZ.  
Values are given as n and (%). 
 
Chronic inflammation 
 
Pathologist 1 
 
IFD/n (%) 
Pathologist 2 
 
IFD/n (%) 
1 0/17 (0) 1/20 (5) 
2 1/6 (17) 1/5 (20) 
3 1/6 (17) 2/4 (50) 
 
Comments 
 
The Ileal Pouch 
 
In a review of the literature including 2040 patients from 23 studies, the pooled 
prevalence of dysplasia was 1,13 (0-18,75)%270. A nationwide study from 
Holland reported a cumulative incidence of pouch neoplasia of 3.7% after 15 
years and 6.9% after 20 years73. The large study from Cleveland Clinic reported 
that 0.6% of the patients operated on for chronic colitis was recorded with 
pouch neoplasia; however, 3.2% after 10 years was recorded for patients 
operated on for dysplasia or carcinoma72. The cumulative incidence of neoplasia 
was 2.2% for patients without prior colorectal carcinoma and 29.5% for patients 
with prior colorectal carcinoma72. Previous reports of dysplasia in ileal pouches 
in patients with neoplasia in their proctocolectomy specimen (studies from 
2000) are displayed in Table 7. In the studies by Kariv72 and Derikx73, patients 
identified postoperatively cannot be separatley identifed. 
 
Table 7. Cases with dysplasia in the ileal pouch in patients with previous neoplasia. 
 
Reference No Duration 
IBD, y 
Duration 
follow-up, y 
Dysplasia [n] Prevalence 
Kupier 
2008168 
44 
 
3-23 
med 13 
3-14 
med 9 
1 LGD/HGD 2.2% 
Kariv 
201072 
492 NA NA 2 dysplasia 0.4% 
Derikx 
201373 
163 NA NA 4 LGD 
 
2.5% 
Block 
2014 
 56 
 
8-57 
med 31 
1-29 
med 18 
1 LGD/0* 1.8%/0* 
y, years; NA, not available; med, median; mo, months; post-op, postoperative 
* Two independent pathologists 
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The ATZ 
 
Previous reports of dysplasia in patients with neoplasia in their proctocolectomy 
specimen in the ATZ (studies from 2000) are displayed in Table 8. The results 
of the current study are in accordance with previous ones. 
 
Table 8. Cases with dysplasia in the ATZ in patients with previous neoplasia. 
 
Reference No Duration 
IBD, y  
Duration 
follow-up, y 
Dysplasia Prevalence 
Kupier 
2008168 
44 
 
3-23 
med 13 
3-14 
med 9 
1 IFD 
 
2.2% 
Kariv 
201072 
492 NA NA 16 
dysplasia 
3.3% 
Derikx 
201373 
163 
 
NA NA 0 
 
0 
Block 
2014 
 56 
 
8-57 
med 31  
1-29  
med 18  
0 0 
y, years; NA, not available; med, median 
 
The clinical significance of IFD remains to be elucidated. Some studies include 
IFD in their analysis168,270, while others do not72,73.  IFD is not consider as a 
premalignant lesion during ordinary UC surveillance (colonoscopy) with a very 
low risk of progression to neoplasia271. Liu et al recommended that IFD in the 
pouch should be treated with antibiotics or anti-inflammatory treatment and 
followed by pouchoscopy every 3-6 months. However, the authors also stated 
that the meaning and impact of IFD is unclear. 
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Differences Between Patients with UC-PSC and 
Patients with UC-only (III) 
 
 
1. Indications for Colectomy  
 
Indi ca t ions  fo r  surgery  were different between the groups. In patients with 
IPAA, dysplasia was the indication for surgery in 23% in patients with UC-PSC 
vs 5% in UC-only.  In the patients with IRA, corresponding figures were 41% 
vs 4%. Sixteen percent of the patients with UC-PSC and IPAA had carcinoma 
as indication for surgery, corresponding data for patients with IRA was 12%. 
Three percent of the patients with UC-only and IPAA (and no patient with 
IRA) had carcinoma as indication for surgery.  
 
Comments 
The results are in accordance with previous ones171,202. It is well known that 
indications for colectomy differs for patients with UC-PSC compared to 
patients with UC-only171,202.  
 
2. Functional Outcome after IPAA or IRA  
 
For IPAA , there was no difference between patients with UC-PSC and patients 
with UC-only. For patients with UC-PSC, 6 (25%) of the patients had a score 
≥8 compared to 7 (12%) in patients with UC-only.  
 
For patients with IRA , the score was significantly worse for patients with UC-
PSC compared to patients with UC-only (see Table 9). In patients with UC-PSC 
2 (25%) had a score ≥8, compared to 3 (8%) with UC-only.  
 
Comments 
IPAA:  There are only two previous studies on IPAA function in patients with 
UC-PSC205,211. Kartheuser et al205 reported a mean daytime stool frequency of 6 
(range 1-10), similar to that of patients with UC-only. Also in the other study, 
(65 patients with UC-PSC compared to 260 patients with UC-only), functional 
outcome was similar between the groups211.  
As recorded by others206,208-210, patients with UC-PSC had significant more 
episodes of pouchitis (see below). Pouchitis is regularly associated with 
deteriorated functional outcome102,272. However, no such effect was observed in 
the present study.  
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IRA:  The number of patients with UC-PSC and IRA in the functional analysis 
was small. However, patients with UC-PSC had significant worse function than 
patients with UC-only, see Table 9. The functional score for the patients with 
UC-only are roughly in accordance with previous reports40,52. 
No previous study has explored this topic. Considering the significant 
differences (bowel movement frequency and urgency), the most obvious 
explanation for the impaired function in patients with UC-PSC would be a 
higher frequency of proctitis41,51. Surprisingly, we did not find an obvious 
correlation between proctitis and functional outcome (see below, Procitis). 
 
Table 9. Functional outcome IRA. 
 
Feature 
 
Rating UC- 
PSC 
UC- 
only 
  IRA 
n=8 
IRA 
n=39 
Bowel movements [n (%)] 
during daytime 
≤4 
5 
≥6 
 
 
0 
1 
2 
 
 
2 (25) 
0 
6 (75) 
 
 
12 (31) 
20 (51) 
7 (18)* 
Bowel movements [n (%)] 
during night-time 
0 
1/week 
≥2/night 
 
 
0 
1 
2 
 
 
0 
3 (38) 
5 (62) 
 
 
20 (51) 
13 (33) 
6 (15)** 
Urgency [n (%)] 1 4 (50) 1 (3)*** 
Social handicap [n (%)] 1 4 (50) 2 (5)**** 
Median score (range) 
≥8 
7 (2–11) 
2 (25) 
3 (0–11)# 
3 (8) 
 * p=0.003, ** p=0.014, *** p=0.0018, **** p=0.005, # p=0.005 
 
 
3. Pouchitis  
 
Details of pouchitis are displayed in Table 10. Significantly more patients with 
UC-PSC had experienced pouchitis compared to patients with UC-only. 
Furthermore, four episodes of pouchitis or more, was more common in patients 
with UC-PSC. Patients with UC-PSC had shorter time to pouchitis and more 
patients experienced their first episode within one year.  
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 Table 10. Clinicopathological characteristics of pouchitis among the groups. 
 
Pouchitis UC- 
PSC 
n=31 
UC- 
only 
n=62 
Patients with pouchitis [n (%)] 27 (87) 
 
20 (32)* 
No episodes [n (%)] 
 
4 (13) 42 (68)* 
 
1–3 episodes [n (%)] 
 
7 (26) 
 
12 (60) 
 
≥4 episodes [n (%)] 
 
20 (74) 
 
8 (40)** 
 
Time to pouchitis, years [median (range)] 1 (1–11) 
 
3.4 (0.5–16) 
 
First episode within 1 year of surgery  
[n (%)] 
17/26 
(65%) 
6/20 
(30%) 
Failure due to pouchitis [n (%)] 3 (11) 
 
0 
 
* p<0.001,  ** p=0.001 
 
 
Comments 
 
Six previous studies have explored pouchitis in patients with UC-PSC (Table 
11).  
 
The current results support the theory that patients with UC-PSC have an 
increased risk for pouchitis. Considering previous studies, choosed method for 
diagnosis was solely clinical in one study212, and based on histology in two210,211. 
Clinical criteria was combined with histology in two studies208,209, the method 
was not stated in one205.  Three studies found that PSC was associated with 
chronic pouchitis208-210, while two did not211,212. One study was uncontrolled205. 
Most studies suggest that pouchitis is more common in patients with PSC, 
however not all.  
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Table 11. Pouchitis in patients with PSC – previous studies. 
____________________________________________________________________________ 
Study % Definition of  Follow-up 
 of pouchitis chronic pouchitis 
____________________________________________________________________________ 
Kartheuser 50% Not stated  71 months        
1993213 
     
Penna 1996208 63% in PSC  >2 episodes +  Mean 62.5                 
 32% in controls antibiotic>15 days months 
 Chronic per month  (12-144)    
 60% vs 15%  
   
Aitola 1998209 90% in PSC Either 6 episodes per Median 64        
 30% in controls year or need for   months  
 Chronic suppressive medical (12-102) 
70% vs 11% therapy 
 
Gorgun 2005211 14% in PSC 1) 4 episodes/year  68±50 months 
 12% in 2) symptoms 4 weeks (UC-PSC) 
 controls 3) chronic therapy  102±62 months 
    (UC-only)  
Lepistö 2008210 48% in PSC  Not stated  Median 9 years        
 26% in controls   (3-14) 
           
Hoda 2008212 PSC not assoc.  3 episodes per year and Not clear 
to chronic antibiotic/antiinflam         
 pouchitis  
             
Block 2013 87% in PSC  >4 times/year   Median 11 years 
 32% in control   (0-26) UC-PSC 
 Chronic    Median 14 years  
 74% vs 40%   (1-25) UC-only  
____________________________________________________________________________ 
 
4. Proctitis 
 
There was a correlation between the Mayo score and the histopathological 
score, but no obvious correlation between the Mayo score and the Öresland 
score. The three patients with the lowest Mayo scores (0, 0 and 1) had Öresland 
scores 2, 7 and 11, while the three patients with the highest Mayo scores (5, 6 
and 6) had Öresland scores 2, 6 and 8.  
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Comments 
 
There are no previous studies on the association between rectal function and 
proctitis (evaluated by endoscopy) in patients with UC-IRA.  
 
5. Surgical Complications  
 
There were no significant differences between patients with UC-PSC and 
patients with UC-only. For patients with IPAA, the most common 
complications were stricture of the ileo-anal anastomosis, followed by small 
bowel obstruction. For patients with IRA, the most common complications 
were anastomotic dehiscence and small bowel obstruction.  
 
Comments 
  
Patients with IPAA: 
A few studies (mainly retrospective) have recorded surgical complications after 
IPAA in patients with UC-PSC. Mathis et al206 found a complication rate of 
39% after 6 years. In the case-control study (UC-PSC vs UC-only) by Gorgun et 
al211, a complication rate of around 50% was found in both groups; however, 
pelvic sepsis was more frequent in patients with UC-PSC (14% vs 5%)211. 
Kartheuser et al213 concluded that patients with UC-PSC have more long-term 
complications; the rate was 55%213 (compared with their previous results in 
patients with UC-only of 29%)273. The authors found it of outmost importance 
that liver function is stable at time of surgery213. The current study demonstrates 
a complication rate of around 50% after 10 years, with no difference between 
patients with UC-PSC and patients with UC-only. The results are thus similar to 
the ones found by Mathis and Gorgun206,211.  
Although the literature is sparse, it cannot be concluded that patients with UC-
PSC suffer more frequently from post-operative complications, than patients 
with UC-only. 
 
Patients with IRA 
The complication rate for patients with IRA and UC-only is in accordance with 
previous reports40,52. No previous study has reported outcome after IRA for 
patients with UC-PSC. Although the number of patients is small, there was 
seemingly a trend towards a higher complication rate in this group. 
 
6. Failure 
 
For patients with IPAA, there was no difference in failure rate between patients 
with UC-PSC and patients with UC-only.  
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For patients with IRA however, a significant difference was recorded (Table 12).  
 
Table 12. Failure IPAA/IRA. 
 
Failure IPAA 
 
IRA 
 UC- 
PSC 
UC- 
only 
UC- 
PSC 
UC- 
only 
No. of patients with failure 
[n (%)] 
5/31  
(16) 
4/62  
(6) 
9/17  
(53) 
11/51 
(22)* 
*p=0.03 
 
 
Comments 
Failure after IPAA  is a well-known problem (see Introduction). The failure rate 
in patients with UC-only is in accordance with previous reports35,36,129. No 
previous study has explored the failure rate in patients with UC-PSC. 
Interestingly, the increased rate of pouchitis in patients with UC-PSC was 
seemingly not associated with more failures.  
For patients with IRA , the failure rate in patients with UC-only fits well with 
previous findings40,41,52,54. As, for IPAA, no previous study has explored this 
topic in patients with UC-PSC. The outcome of IRA in patients with UC-PSC is 
disappointing, but they should be interpreted with caution since the number of 
patients is low. However, IRA should probably be considered as a temporary 
solution in this group. 
 
 
Galectin Variations in Ulcerative Colitis (IV) 
 
Galec t in -1  was not expressed in colon epithelial cells or in inflammatory cells. 
 
Galec t in -2  was strongly expressed in the entire cytoplasm of colon epithelial 
cells in controls without any individual variation. In the UC-colon, the 
expression was identical in patients with mild and moderate inflammation. 
Patients with severe inflammation showed a reduced to minimal expression. 
Around half of the inflammatory cells showed a weak expression and almost all 
strongly positive cells were macrophages.  
 
Galec t in -3  was strongly expressed in control tissue, showing a typical gradient 
with strong surface epithelial expression. The same gradient was observed in 
UC-colon. We observed a diminished expression in some patients with mild and 
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moderate inflammation but the majority with severe inflammation showed a 
similar expression as the control group. A strong expression was seen in very 
few of the inflammatory cells and 10-15% showed a weak expression. The 
majority of positive cells were macrophages.  
 
Galec t in -4  showed a different pattern of staining with a typical supra-nuclear 
distribution, both in controls and UC. The expression was strong in the control 
tissue. We observed a decreased galectin expression with increased inflammatory 
activity. However, there was a great inter-individual variation. Galectin-4 was 
not present in inflammatory cells.  
 
Galec t in  expres s ion  r e la t ed  to  in f lammat ion grade .  In conclusion, we did not 
find any clear correlation between the galectin expression and the severity of 
inflammation among the UC patients. Instead, we observed heterogenic patterns 
among the majority of patients. 
 
Comments 
 
Previous studies have implicated galectins in patients with IBD as potential 
markers of disease as well as potential theurapeutic agents. The majority of 
previous data is from experimental animal models235,240,274,275 and thus the 
clinical significance in the human situation is uncertain. Published clinical studies 
are limited regarding the number of patients included and their clinical status as 
well as their pharmacological treatment250,251. The method of choice to evaluate 
galectin expression has been immunohistochemical semi quantitative grading of 
immunohistochemistry215. However, this approach still needs to be improved in 
terms of standardization of immunohistochemical procedures (different 
available antibodies) and the staining evaluation (objective and adapted scoring 
system)215. Comparing results from different studies are therefore difficult. 
Alternatively, galectins can be analyzed with qualitative analysis, i.e. mRNA 
reverse transcription techniques228, Western blot253 and/or flourescence 
activated cell sorter (FACS)250,253.  
 
We analysed the entire intestinal wall wich gave the ability to evalute large tissue 
areas, illustrating the focality of the disease (see Fig. 2 in paper IV). Therefore, 
interpretation of small biopsies should be evaluated carefully and their 
representativity can be questioned. Furthermore, with increased amount of 
inflammation, the cell loss increases and therefore changes in the galectin 
expression can solely be due to loss of intestinal epithelial cells.  
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GENERAL DISCUSSION 
The Optimal IPAA – Technical Aspects 
IPAA function is a complex parameter depending on several factors and it 
affects the patients QoL145. The surgeon can improve the functional outcome in 
performing meticulous surgery, avoiding complications, and by constructing the 
pouch and the ileo-anal anastomosis in an optimal fashion. Furthermore, 
technical aspects can have impact on future surveillance (see below).  
This thesis shows that the K -pouch is associated with better long-term 
functional outcome than the J-pouch, and that the stapled anastomosis is 
associated with better long-term functional outcome than the hand-sewn. 
Although the difference is significant, the clinical relevance is unclear. It would 
be a bold statement to recommend the international surgical community to 
perform K -pouches as standard procedure. Compared to the J-pouch, the K -
pouch is technically more complex to perform. Introduction of the procedure 
could be associated with complications during the learning curve. However, in 
an unit that regularly performs CI:s, it is an excellent way to keep up the 
competence for the CI procedure, since IPAA with K -design is constructed in 
the same way as a CI (omitting the nipple segment). 
It is well known that the stapled ileo-anal anastomosis has better functional 
outcome than the hand-sewn67,68,136. The stapled anastomosis is easier to 
construct, associated with less postoperative complications67 and is easier to 
survey (see below). Some authors recommend that a mucosectomy and hand-
sewn anastomosis should be performed when dysplasia is indication for surgery, 
especially when dysplasia is present in the lower third of the rectum70. However, 
several studies have shown that mucosectomy do not seem to be completely 
protective against rectal remnants; thus, there could still be a risk of dysplasia. 
Accordingly, the anastomosis of choice should be the stapled one. However, if 
the stapled anastomosis fails due to technical problems, or if the disease 
(Familial Adenomatous Polyposis or neoplasia) is localized to the very distal 
rectum, knowledge of how to perform mucosectomy and hand-sewn 
anastomosis is mandatory. 
Surveillance of Neoplasia in Patients with IPAA? 
Surveillance of neoplasia in patients with IPAA is a delicate issue with several 
aspects to consider.  
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The Association Between Dysplasia and Carcinoma 
General surveillance of patients with IPAA without increased risk for neoplasia 
does not seem indicated. The number of patients with IPAA worldwide is 
constantly increasing and the cases with carcinoma are few. Carcinomas are 
probably never going to be the aim for a surveillance program; such a program 
has to focus on patients with increased risk for dysplasia. The problem with that 
strategy is that it is based on the assumption that dysplasia is a risk factor for 
carcinoma. Considering the ileal pouch, the association has to be demonstrated.  
The Estimated Frequency of Dysplasia  
Several studies have indicated that the risk for dysplasia in patients without risk 
factors is low. Patients with neoplasia in the proctocolectomy specimen are 
probably the only group where it seems rational to consider surveillance. The 
upper limit of the 95%-confidence interval for the frequency of dysplasia in the 
IPAA in the current study is around 5% and the study by Kariv72 indicates that 
the risk could be even higher in patients with carcinoma in the specimen. The 
problem is the obvious discrepancy between the estimated frequencies of 
dysplasia and the observed numbers of patients with carcinomas related to 
IPAA:s.  
Review of Specimen 
It seems reasonable to suggest that patients with dysplasia in the 
proctocolectomy specimen could be considered for surveillance. Inclusion in the 
program is thus going to depend on the pathology report.  In the current study, 
around 50% of the patients were identified postoperatively, during routine 
review of the specimen. If surveillance is suggested, the importance of the 
pathology report has to be emphasised. The routines for management of these 
specimens should be optimised and the quality increased.  
Method for Surveillance - Pouchoscopy 
Many patients experience pouchoscopy as a discomfort and evaluation of the 
ATZ is the major problem, especially in patients with hand-sewn anastomosis. 
Furthermore, since the majority of dysplasias and carcinomas are in the ATZ:s, 
it seems reasonable to have specific focus on this area70,166,184. Some authors 
recommend examination under anaesthesia72; however, in today health-care, this 
is not feasible. Furthermore, routine anaesthesia would considerably increase the 
risks associated with the program. There is a risk for bleeding and perforation 
when performing biopsies. Although the risk seems small, it should be 
considered, since the effects could have dramatic effects for the patient. 
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Discomfort and risks associated with pouchoscopy will probably effect patient 
compliance throughout the program.  
Dysplastic lesions are hard to discover and can present in several ways. There 
are no obvious characteristic features of the lesions, and (the common) 
concurrent inflammation makes the task even more difficult. Thus, there is 
clearly a detection problem in routine endoscopy72. Chromo endoscopy has 
been evaluated but no increase in detected cases with dysplasia was found168. 
Polyps and lesions should be biopsied and polypectomy should be performed in 
lesions>1 cm, since neoplasia could be present in around 10% of these276. 
Interestingly, in case reports on pouch carcinomas, around one third of the 
patients lack visible lesions72. Therefore, blind biopsies are advocated.  
Alternative techniques have been suggested for early detection of pouch 
neoplasia. These techniques include biopsy recordings of DNA abnormalities 
such as mutations of p53, APC genes, k-ras, aneuploidy and lost of 
heterozygosis87,170,173,185,277. Stool DNA tests have been used in screening for 
colorectal carcinoma and can be efficient in that setting278. However, these data 
cannot be applied on patients with IPAA.  
Routine pouchoscopy is thus associated with several problems and cannot be 
considered a satisfactory method for surveillance. Improvement of the current 
technique and development of alternative ones are important future aspects.  
Management of Patients with Dysplasia 
There are established routines when a patient with UC is identified with LGD or 
HGD in the colon-rectum159:  
a. Two experienced pathologists should review the biopsies.  
b. Follow up visits should be performed more often when LGD is recorded.  
Considering patients with IPAA, it seems reasonable to adopt these parts of the 
routines. Recording of HGD is usually considered indication for surgery. When 
HGD is present (in repeated biopsies) in the ATZ, resection should be 
suggested. Perhaps the most difficult case is a patient with HGD in the ileal 
pouch; it seems easy to suggest resection. However, the evidence for pouch 
excision in this situation is poor (and the patient is going to suffer deteriorated 
QoL). A thorough discussion with the patient is mandatory.  The significance of 
IFD remains to be elucidated. Keeping with the guidelines for surveillance of 
colon-rectum in patients with UC, IFD is without significance in the ATZ159. 
However, when IFD appears in the ileal pouch, the literature is not consistent. 
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According to Liu et al, the patient should be monitored more closely (3-6 
months) and treated with anti-inflammatory drugs, or antibiotics165. Kupier et 
al., and Scarpa et al., also recommend closer survey168,270. In contrast, the two 
largest studies, Derikx et al73 and Kariv et al72 excluded IFD from their analysis. 
Since the evidence is poor, it seems reasonable to be on the safe side and 
suggest that IFD in the ileal pouch is managed as LGD.  
In conclusion, surveillance or not in patients with IPAA is still a matter of 
debate. The proposed risk group (previous nepolasia) is small. However, 
prospected studies on the efficacy and costs seem more reasonable than routine 
implementation.  
Management of the Patients with UC-PSC after Abdominal 
Colectomy  
There are no randomized trials on the two major options (IPAA and IRA) after 
abdominal colectomy for patients with UC-only. Considering the much smaller 
group with UC-PSC, clinical decisions are thus going to rely on low evidence 
data. Another important aspect is that the complication rate is very high when 
colorectal surgery is performed in patients with concurrent liver cirrhosis; 
furthermore, significant postoperative mortality has been reported in this 
group279. 
After abdominal colectomy, IPAA seems to be the preferred option for patients 
with UC-PSC. The patient should be informed that most studies demonstrate an 
increased risk for pouchitis. However, there is no data favouring that the 
increased frequency of pouchitis is followed by an increased rate of pouch 
failure. Interestingly, the course of colitis in patients with UC-PSC is usually 
considered quiescent compared to patients with UC-only; the course of 
pouchitis may follow the same pattern. Aggressive treatment of pouchitis has 
been suggested212. Patients with UC-PSC and pouchitis have, in some studies, 
been considered as a risk group for dysplasia and thus suggested for 
surveillance. The data on IRA in patients with UC-PSC is sparse. In the current 
study IRA was associated with poor functional outcome high risk for failure. 
However, the study is small and there is an obvious risk for patient selection.  
Finally, after abdominal colectomy, QoL should be evaluated in future studies 
on patients with UC-PSC. 
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CONCLUSIONS 
 
• K -pouch with stapled anastomosis gives the best long-term functional 
outcome. The difference compared to other pouch designs is small and 
the study is non-randomised. 
 
• The incidence of pouch neoplasia is low in patients with previous 
neoplasia in the colorectal specimen. 
 
• The value of screening for neoplasia in patients with IPAA can be 
questioned and prospective studies are warranted. 
 
• The outcome of IPAA in patients with UC-PSC is similar to outcome 
in patients with UC-only, except for an increased risk for pouchitis.  
 
• IRA in patients with UC-PSC is associated with worse functional 
outcome and high failure rate. The study is small and there is a risk for 
patient selection. 
• Galectin expression in patients with UC seems to be 
depending more on disease focality and individual variation, 
rather than tissue inflammation grade. 
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SUMMARY IN SWEDISH -
SAMMANFATTNING PÅ SVENSKA 
Bakgrund 
Ulcerös Colit (UC) är en kronisk tarmsjukdom som kännetecknas av 
inflammation i slemhinnan inom kolon-rektum. Genesen är i huvudsak okänd 
och komplex; en samverkan mellan genetiska och immunolgiska faktorer, 
tarmfloran och en förändrad permeabilitet i tarmväggen är de mest troliga 
patofysiologiska mekanismerna. Incidensen i Sverige är ca 10-15/100 000 och 
år. Insjuknandet sker vanligtvis i 20-35 årsåldern och sjukdomen drabbar 
kvinnor i något högre omfattning (1.2:1). Den initiala behandlingen av UC är 
medicinsk, men i ca 30% av fallen krävs kirurgisk behandling. Den vanligaste 
operationsmetoden är proktokolektomi med anläggande av bäckenreservoar 
(IPAA), men ett annat alternativ är ileorektal anastomos (IRA).  
Detta avhandlingsprojekt studerar långtidsresultaten efter operation med IPAA, 
fokuserat på reservoarkonstruktionens betydelse för det funktionella resultatet 
och risken för att utveckla dysplasi i IPAA:n. En speciell patientgrupp är den 
med UC i kombination med primär skleroserande kolangit (PSC; UC-PSC), i 
denna grupp har vi studerat utfallet av IPAA och IRA och jämfört med UC-
patienter utan PSC (UC-only). De kliniska studierna har kompletterats med en 
experimentell studie, där uttrycket av galektiner (kolhydratbindande proteiner) 
analyserats i kolorektala preparat hämtade från patienter med UC.  
Frågeställningar 
Skiljer sig det funktionella resultatet sig åt mellan olika IPAA-konstruktioner? (I) 
Hur hög är frekvensen dysplasi i IPAA:n bland patienter som hade dysplasi eller 
cancer i sin bortopererade tarm? (II) 
Skiljer sig utfallet av operation med IPAA eller IRA mellan patienter med UC-
PSC och patienter med UC-only? (III) 
Finns det en korrelation mellan galektin-uttrycket och graden av inflammation 
hos patienter med UC? (IV) 
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Metod 
I: Reservoaren kan konstrueras på olika sätt (J  eller K ); det samma gäller den 
ileo-anala anstomosen (staplad [S ] eller handsydd [H ]). Patienterna rekryterades 
från Svenska Kolitoperationsregistret (numera SwibReg-Swedish Inflammatory 
Bowel Disease Registry) och fick besvara frågeformulär för utvärdering av 
bäckenreservoarens funktion (Öresland score).  
II: Ur samma register (I, ovan) identifierades patienter opererade med IPAA och 
med dysplasi eller cancer i sin bortopererade tarm. Patienterna erbjöds 
deltagande i studien (klinisk undersökning, endoskopi av bäckenreservoaren, 
samt biopsitagning). Biopsierna granskades av två oberoende patologer. Akut 
och kronisk inflammation, indefinite for dyspalsia (IFD), låggradig dysplasi 
(LGD), höggradig dysplasi (HGD) och cancer registrerades.  
III: En kohort med patienter med UC-PSC jämfördes med patienter med UC-
only från registret (ovan, I). Funktion (Öresland score), frekvenser av pouchit, 
komplikationer och failure analyserades.  
IV: Patienter med operationskrävande UC inkluderades konsekutivt i en IBD-
biobank; fullväggspreparat analyserades. Patienter med cancer eller 
funktionsrubbning fungerade som kontroller. Inflammationsgraden 
klassificerades som mild (cryptit), måttlig (abscess) eller svår (ulceration). Det 
immunohistokemiska galektin-1 till -4-uttrycket semikvantifierades okulärt från 
inget (0) till starkt (3). 
Resultat och slutsatser 
 
I: 412 patienter inkluderades; svarsfrekvensen var 87%. Signifikanta skillnader 
förelåg mellan KH  och JH  samt mellan KS  och JS/JH . Regressionsanalys 
visade att reservoartyp och ålder vid operation hade betydelse för funktionen. 
I  de t ta  i cke-randomiserade ,  men s tora  pat i en tmater ia l ,  var  IPAA-
konstrukt ion med s tap lad K-res e rvoar  fö r enad med de t  bäs ta  funkt ione l la  
lång t idsr e su l ta t .  
II: 56/90 (39 män) möjliga patienter inkluderades i studien. Den ena patologen 
fann 19 patienter med IFD, den andra 20, det var full samstämmighet i 45 (80%) 
av patienterna. En patolog fann LGD hos en patient i bäckenreservoaren (1.8% 
[95% CI: 0-5.3%]). Inget fall med HGD eller cancer hittades.  
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Frekvensen  av  dysp la s i  hos  pat i en t e r  med IPAA är låg ,  även i  denna 
utpekade r i skgrupp ( t id igare  dysp las i/cancer ) .  Övervakningsprogram för  
den aktue l la  gruppen behöver  u tvärderas  prospekt iv t .     
III: 48 patienter (31 IPAA, 17 IRA) med UC-PSC jämfördes med 113 patiener 
med UC-only (62 IPAA, 51 IRA). Funktionen för IPAA-patienterna skiljde sig 
inte mellan grupperna. För patienterna med IRA var funktionen sämre i UC-
PSC-gruppen. Pouchit var vanligare i UC-PSC-gruppen. Hos patienter med IRA 
var frekvensen failure 53% i UC-PSC-gruppen, jämfört med 22% bland 
patienter med UC-only.  
Pat i en t e r  med UC-PSC och IPAA har s törr e  r i sk för  pouch i t .  Pat i en t e rna 
med IRA och UC-PSC är  få  o ch  r e su l ta t en  där för  osäkra ,  men IRA 
före fa l l e r  vara  e t t  a l t e rnat iv  asso c i e ra t  med då l i g  funkt ion o ch  hög  r i sk för  
fa i lure .   
IV: 22 konsekutiva patienter (8 män) med UC samt en kontrollgrupp (n=8), 
inkluderades i studien. Vi fann ingen säker korrelation mellan inflammationsgrad 
och galektinuttryck.  
Uttry cket  av  de  ana ly s erade  ga l ekt inerna uppv i sar  ingen tyd l i g  korre la t ion  
med graden av  k l in i sk e l l e r  h i s to log i sk in f lammat ion .  Varia t ionen i  
ga l ekt in -u t t ry cke t  fö r e fa l l e r  snarare  vara  e t t  u t t ry ck för  fö r lus t  av  
ep i t e l ia la  c e l l e r  o ch/e l l e r  ind iv idue l la  eg enskaper  hos  den enski lda 
pat i en t en .  
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